Literature DB >> 11736948

Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients.

S Maury1, J Y Mary, C Rabian, M Schwarzinger, A Toubert, C Scieux, M Carmagnat, H Esperou, P Ribaud, A Devergie, P Guardiola, P Vexiau, D Charron, E Gluckman, G Socié.   

Abstract

To evaluate the long-term immune reconstitution after allogeneic haematopoietic stem cell transplantation (SCT), we prospectively screened standard immune parameters in a series of 105 patients, at a median time of 15 months after SCT. Analysing lymphoid phenotypes, in vitro immune functions and immunoglobulin levels, we found that, more than 1 year post SCT, cellular and humoral immunity was still altered in a significant number of patients. CD4+ T cells were < 200/microl in one third of patients, and the CD4/CD8 ratio was still reversed in 78% of patients. Almost all patients showed positive T-cell responses against mitogens, but antigen-specific proliferation assays identified 20% to 80% of non-responders. B-cell counts were reconstituted in 61% of the patients, but levels of total immunoglobulins were still low in 59%. In multivariate analyses, human leucocyte antigen (HLA) disparity between donor and recipient and chronic graft-versus-host disease were the leading causes affecting immune reconstitution. Interestingly, cytomegalovirus (CMV) infections were strongly associated with normal CD8+ T-cell counts. Studying the impact of impaired immune reconstitution on the rate of infections occurring in the 6 years following screening, we identified three parameters (low B-cell count, inverted CD4/CD8 ratio, and negative response to tetanus toxin) as significant risk factors for developing such late infections.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11736948     DOI: 10.1046/j.1365-2141.2001.03135.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  48 in total

Review 1.  Adoptive precursor cell therapy to enhance immune reconstitution after hematopoietic stem cell transplantation.

Authors:  J L Zakrzewski; A M Holland; M R M van den Brink
Journal:  J Mol Med (Berl)       Date:  2007-02-28       Impact factor: 4.599

Review 2.  The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Miriam Ciáurriz; Amaya Zabalza; Lorea Beloki; Cristina Mansilla; Estela Pérez-Valderrama; Mercedes Lachén; Eva Bandrés; Eduardo Olavarría; Natalia Ramírez
Journal:  Cell Mol Life Sci       Date:  2015-07-15       Impact factor: 9.261

Review 3.  The role of the thymus in allogeneic bone marrow transplantation and the recovery of the peripheral T-cell compartment.

Authors:  Enrico Velardi; Emmanuel Clave; Franco Locatelli; Antoine Toubert; Lucas C M Arruda; Francesca Benini
Journal:  Semin Immunopathol       Date:  2021-01-08       Impact factor: 9.623

4.  Adoptive therapy with CMV-specific cytotoxic T lymphocytes depends on baseline CD4+ immunity to mediate durable responses.

Authors:  Vanessa A Fabrizio; M Irene Rodriguez-Sanchez; Audrey Mauguen; Parastoo B Dahi; Ekaterina Doubrovina; Richard J O'Reilly; Susan E Prockop
Journal:  Blood Adv       Date:  2021-01-26

5.  Invariant natural killer T cells generated from human adult hematopoietic stem-progenitor cells are poly-functional.

Authors:  Wenji Sun; Yi Wang; James E East; Amy S Kimball; Katherine Tkaczuk; Susan Kesmodel; Scott E Strome; Tonya J Webb
Journal:  Cytokine       Date:  2015-01-05       Impact factor: 3.861

Review 6.  Sex steroid ablation: an immunoregenerative strategy for immunocompromised patients.

Authors:  E Velardi; J A Dudakov; M R M van den Brink
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

7.  Simian varicella virus in pigtailed macaques (Macaca nemestrina): clinical, pathologic, and virologic features.

Authors:  Renee Rosemary Hukkanen; Maggie Gillen; Richard Grant; H Denny Liggitt; Hans-Peter Kiem; Stephen T Kelley
Journal:  Comp Med       Date:  2009-10       Impact factor: 0.982

8.  Bone marrow B cell precursor number after allogeneic stem cell transplantation and GVHD development.

Authors:  Yuri Fedoriw; T Danielle Samulski; Allison M Deal; Cherie H Dunphy; Andrew Sharf; Thomas C Shea; Jonathan S Serody; Stefanie Sarantopoulos
Journal:  Biol Blood Marrow Transplant       Date:  2012-03-20       Impact factor: 5.742

Review 9.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

10.  Outcome and prognostic indicators of patients with hematopoietic stem cell transplants admitted to the intensive care unit.

Authors:  Thanh N Huynh; S Sam Weigt; John A Belperio; Mary Territo; Michael P Keane
Journal:  J Transplant       Date:  2009-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.